Related references
Note: Only part of the references are listed.Cross-Talk of Receptor Activator of Nuclear Factor-κB Ligand Signaling With Renin-Angiotensin System in Vascular Calcification
Mariana Kiomy Osako et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
The Role of Serum Osteoprotegerin and S-100 Protein Levels in Patients with Acute Ischaemic Stroke: Determination of Stroke Subtype, Severity and Mortality
M Üstündağ et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2013)
Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients
Tae-Jin Song et al.
BIOMARKERS (2012)
Inflammatory cytokines in experimental and human stroke
Kate Lykke Lambertsen et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2012)
The expression of osteoprotegerin is required for maintaining the intervertebral disc endplate of aged mice
Qian-Qian Liang et al.
BONE (2011)
Osteoprotegerin in Sputum Is a Potential Biomarker in COPD
Masako To et al.
CHEST (2011)
Effects of RANKL on the thymic medulla
Izumi Ohigashi et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
TLR2-dependent Modulation of Osteoclastogenesis by Porphyromonas gingivalis through Differential Induction of NFATc1 and NF-κB
Ping Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Do RANKL inhibitors (denosumab) affect inflammation and immunity?
S. Ferrari-Lacraz et al.
OSTEOPOROSIS INTERNATIONAL (2011)
Estrogen Inhibits Vascular Calcification via Vascular RANKL System Common Mechanism of Osteoporosis and Vascular Calcification
Mariana Kiomy Osako et al.
CIRCULATION RESEARCH (2010)
Osteoprotegerin concentrations and prognosis in acute ischaemic stroke
J. K. Jensen et al.
JOURNAL OF INTERNAL MEDICINE (2010)
Key Role of CD36 in Toll-Like Receptor 2 Signaling in Cerebral Ischemia
Takato Abe et al.
STROKE (2010)
Evaluation of Pharmaceuticals With a Novel 50-Hour Animal Model of Bone Loss
Yoshiya Tomimori et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2009)
Central control of fever and female body temperature by RANKL/RANK
Reiko Hanada et al.
NATURE (2009)
Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke
Arthur Liesz et al.
NATURE MEDICINE (2009)
Temporal and Spatial Dynamics of Cerebral Immune Cell Accumulation in Stroke
Mathias Gelderblom et al.
STROKE (2009)
Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells
Karin Loser et al.
NATURE MEDICINE (2006)
Receptor activator of NF-κB ligand and osteoprotegerin regulate proinflammatory cytokine production in mice
Kenta Maruyama et al.
JOURNAL OF IMMUNOLOGY (2006)
RANKL in human periapical granuloma:: possible involvement in periapical bone destruction
R. Vernal et al.
ORAL DISEASES (2006)
Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor
N Yamada et al.
CYTOKINE (2005)
New molecules in the tumor necrosis factor ligand and receptor superfamilies with importance for physiological and pathological bone resorption
UH Lerner
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE (2004)
Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway
S Lehnardt et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Receptor activator NF-κB ligand (RANKL) expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathy, osteoarthritis, and from normal patients:: semiquantitative and quantitative analysis
TN Crotti et al.
ANNALS OF THE RHEUMATIC DISEASES (2002)
Cyclooxygenase-2 inhibitor NS-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity
E Araki et al.
STROKE (2001)
Regional variation in brain capillary density and vascular response to ischemia
M Cavaglia et al.
BRAIN RESEARCH (2001)
Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function
N Udagawa et al.
ENDOCRINOLOGY (2000)
Share Paper
